Nivo40-AVD for Advanced Classic Hodgkin Lymphoma

Sponsor
National Medical Research Radiological Centre of the Ministry of Health of Russia
Study ID
NCT06984146
Phase
PHASE2
Status
Recruiting
Apply to this trial

Conditions

  • Hodgkin Lymphoma, Adult

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Nivolumab — DRUG
    40 mg day 1 and 15
  • Doxorubicin — DRUG
    25 mg/m2 day 1 and 15
  • Vinblastine — DRUG
    6 mg/m2 (not exceeding 10 mg) day 1 and 15
  • Dacarbazine — DRUG
    375 mg/m2 day 1 and 15

Study Details

The aim of the current trial is to evaluate the efficacy and safety of flat-dose nivolumab (40 mg) in combination with AVD in the management of patients with newly diagnosed advanced classic Hodgkin Lymphoma

Key Dates

Start date
Apr 15, 2025
Status verified
Nov 2025
Primary completion
Jan 31, 2028
Completion
Jan 31, 2029

Study Design

Enrollment
54 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Nivo40-AVD
    Nivolumab 40 mg IV day 1 and 15; Doxorubicin 25 mg/m2 IV day 1 and 15; Vinblastine 6 mg/m2 IV day 1 and 15; Dacarbazine 375 mg/m2 day 1 and 15

Primary Outcome Measure

Progression-free survival [ Time Frame: 2 years ]

Central Contacts

Related Studies